Methods
tumor
ADVANCED RENAL CELL CARCINOMA, TUMOR
Progression‐free survival, overall survival, tumor response, and safety were assessed in Japanese patients with previously untreated advanced renal cell carcinoma randomized to receive lenvatinib plus pembrolizumab (